[{"orgOrder":0,"company":"SQ Innovation","sponsor":"SQ Innovation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"SQ Innovation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SQ Innovation \/ SQ Innovation","highestDevelopmentStatusID":"11","companyTruncated":"SQ Innovation \/ SQ Innovation"},{"orgOrder":0,"company":"SQ Innovation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"SQ Innovation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SQ Innovation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"SQ Innovation \/ Undisclosed"},{"orgOrder":0,"company":"SQ Innovation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"SQ Innovation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SQ Innovation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"SQ Innovation \/ Undisclosed"},{"orgOrder":0,"company":"SQ Innovation","sponsor":"Accel Clinical Services","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"SQ Innovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SQ Innovation \/ Accel Clinical Services","highestDevelopmentStatusID":"7","companyTruncated":"SQ Innovation \/ Accel Clinical Services"},{"orgOrder":0,"company":"SQ Innovation","sponsor":"EB Medical Research | Quartesian","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"G3P-01","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"SQ Innovation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SQ Innovation \/ EB Medical Research | Quartesian","highestDevelopmentStatusID":"1","companyTruncated":"SQ Innovation \/ EB Medical Research | Quartesian"},{"orgOrder":0,"company":"SQ Innovation","sponsor":"University of Glasgow | NHS Greater Glasgow and Clyde","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SQIN-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"SQ Innovation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SQ Innovation \/ University of Glasgow | NHS Greater Glasgow and Clyde","highestDevelopmentStatusID":"6","companyTruncated":"SQ Innovation \/ University of Glasgow | NHS Greater Glasgow and Clyde"}]

Find Clinical Drug Pipeline Developments & Deals by SQ Innovation

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Furosemide is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Heart Failure.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 20, 2025

                          Lead Product(s) : Furosemide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Recipient : University of Florida

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Lasix ONYU (furosemide) is a sodium-(potassium)-chloride cotransporter 2 inhibbitor, indicated in adults & pediatric patients for the treatment of edema associated with heart failure.

                          Product Name : Lasix ONYU

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 16, 2024

                          Lead Product(s) : Furosemide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Lasix ONYU (furosemide) is a sodium-(potassium)-chloride cotransporter 2 inhibbitor, being evaluated in adults & pediatric patients for the treatment of edema associated with heart failure.

                          Product Name : Lasix ONYU

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 27, 2023

                          Lead Product(s) : Furosemide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : G3P-01 is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Gastrointestinal Diseases.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          March 25, 2022

                          Lead Product(s) : G3P-01

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Undisclosed

                          Sponsor : EB Medical Research | Quartesian

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : SQIN-01 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Heart Failure.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 15, 2021

                          Lead Product(s) : SQIN-01

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : University of Glasgow | NHS Greater Glasgow and Clyde

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Furosemide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Heart Failure.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 12, 2020

                          Lead Product(s) : Furosemide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Accel Clinical Services

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank